Compare Ascendis Pharma A/S (ASND) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Palo Alto Networks Inc — how do they compare? Ascendis Pharma A/S trades at $254.89 (market cap $16.67B), while Palo Alto Networks Inc trades at $385.25 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 18.8× Ascendis Pharma A/S's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | PANW | |
|---|---|---|
Market Cap | $16.67B | $312.80B |
Sector | Health | Technology |
52-Week High | $277.18 | $385.04 |
52-Week Low | $189.74 | $141.67 |
Enterprise Value | $17.04B | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Palo Alto Networks (PANW) trades at $384.29, down 0.19% on the day, with a bullish technical signal supported by moving averages and strong institutional sentiment. Revenue grew to $9.22B in FY2025, with net income of $1.13B, though valuation ratios like P/E of 333.74 and P/S of 26.64 appear elevated. Recent news highlights AI-driven cybersecurity demand and a China regulatory review, while the company beat EPS estimates in three consecutive quarters.
Outlook remains positive due to robust AI security growth and analyst consensus, but risks include high valuation, integration costs from acquisitions, and geopolitical scrutiny. The stock's proximity to its 52-week high suggests cautious optimism, with upside potential tied to execution on AI initiatives and cybersecurity spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
